Business Description
MorphoSys AG
ISIN : US6177602025
Share Class Description:
MOR: ADRCompare
Compare
Traded in other countries / regions
MOR.USAMOR.Germany0NDV.UK1MOR.ItalyMOR.AustriaMOR.Switzerland IPO Date
2018-04-19Description
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.07 | |||||
| Equity-to-Asset | 0.02 | |||||
| Debt-to-Equity | 12.97 | |||||
| Debt-to-EBITDA | -12.44 | |||||
| Altman Z-Score | 0.41 | |||||
| Beneish M-Score | -3.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.1 | |||||
| 3-Year FCF Growth Rate | -173.8 | |||||
| 3-Year Book Growth Rate | -59 | |||||
| Future 3-5Y Total Revenue Growth Rate | 20.14 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.41 | |||||
| 9-Day RSI | 50.55 | |||||
| 14-Day RSI | 51.46 | |||||
| 6-1 Month Momentum % | 140.16 | |||||
| 12-1 Month Momentum % | 245.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.08 | |||||
| Quick Ratio | 2.84 | |||||
| Cash Ratio | 2.58 | |||||
| Days Inventory | 301.86 | |||||
| Days Sales Outstanding | 98.58 | |||||
| Days Payable | 524.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.7 | |||||
| Shareholder Yield % | 2.14 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.48 | |||||
| Operating Margin % | -105.22 | |||||
| Net Margin % | -79.6 | |||||
| FCF Margin % | -83.05 | |||||
| ROE % | -226.44 | |||||
| ROA % | -8.63 | |||||
| ROIC % | -17.83 | |||||
| ROC (Joel Greenblatt) % | -139.64 | |||||
| ROCE % | -2.94 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.57 | |||||
| PB Ratio | 51.11 | |||||
| EV-to-EBIT | -44.04 | |||||
| EV-to-EBITDA | -49.09 | |||||
| EV-to-Revenue | 10.32 | |||||
| EV-to-FCF | -12.39 | |||||
| Price-to-Median-PS-Value | 0.46 | |||||
| Earnings Yield (Greenblatt) % | -2.27 | |||||
| FCF Yield % | -7.9 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers